 Shares of Optinose Inc. plunged 23 in premarket trading Friday, after the specialty pharmaceuticals company, focused on ear, nose, throat and allergy patients, said its stock offering priced at a deep discount. The company said its offering of 6 million shares, which represents about 13 of the shares outstanding, priced at 5.85 a share, to raise 35.1 million. The pricing was 13.8 below Thursdays closing price of 6.79. The company said it plans to use the proceeds for working capital, including the commercialization and development of XHANCE, a treatment of chronic sinusitis, and the clinical development of OPN-019 for the treatment of COVID-19. The stock offering comes after the stock had run up 74.0 over the past three months through Thursday, while the SP 500 had advanced 18.3. 